148 related articles for article (PubMed ID: 32358822)
1. Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake.
Keunecke A; Hoefman S; Drenth HJ; Zisowsky J; Cleton A; Ploeger BA
Br J Clin Pharmacol; 2020 Dec; 86(12):2362-2376. PubMed ID: 32358822
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
Jain L; Woo S; Gardner ER; Dahut WL; Kohn EC; Kummar S; Mould DR; Giaccone G; Yarchoan R; Venitz J; Figg WD
Br J Clin Pharmacol; 2011 Aug; 72(2):294-305. PubMed ID: 21392074
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies.
Geoerger B; Morland B; Jiménez I; Frappaz D; Pearson ADJ; Vassal G; Maeda P; Kincaide J; Mueller U; Schlief S; Teufel M; Ploeger BA; Cleton A; Agostinho AC; Marshall LV
Eur J Cancer; 2021 Aug; 153():142-152. PubMed ID: 34157616
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models.
Zopf D; Fichtner I; Bhargava A; Steinke W; Thierauch KH; Diefenbach K; Wilhelm S; Hafner FT; Gerisch M
Cancer Med; 2016 Nov; 5(11):3176-3185. PubMed ID: 27734608
[TBL] [Abstract][Full Text] [Related]
5. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.
Gerisch M; Hafner FT; Lang D; Radtke M; Diefenbach K; Cleton A; Lettieri J
Cancer Chemother Pharmacol; 2018 Jan; 81(1):195-206. PubMed ID: 29188322
[TBL] [Abstract][Full Text] [Related]
6. A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors.
Weekes C; Lockhart AC; Lee JJ; Sturm I; Cleton A; Huang F; Lenz HJ
Int J Cancer; 2019 Nov; 145(9):2450-2458. PubMed ID: 30958892
[TBL] [Abstract][Full Text] [Related]
7. The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours.
Lubberman FJE; van der Graaf WTA; Xu L; Cleton A; Demetri GD; Gelderblom H; van Erp NP
Br J Clin Pharmacol; 2019 Oct; 85(10):2399-2404. PubMed ID: 31290566
[TBL] [Abstract][Full Text] [Related]
8. Interaction Between Sex and Organic Anion-Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib-N-Oxide and Regorafenib-Glucuronide in Mice.
Fu Q; Chen M; Anderson JT; Sun X; Hu S; Sparreboom A; Baker SD
Clin Transl Sci; 2019 Jul; 12(4):400-407. PubMed ID: 30955241
[TBL] [Abstract][Full Text] [Related]
9. Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.
Hellmann MD; Sturm I; Trnkova ZJ; Lettieri J; Diefenbach K; Rizvi NA; Gettinger SN
Clin Lung Cancer; 2015 Nov; 16(6):514-22. PubMed ID: 26003007
[TBL] [Abstract][Full Text] [Related]
10. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
Kort A; Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jul; 32(7):2205-16. PubMed ID: 25563977
[TBL] [Abstract][Full Text] [Related]
11. On the population pharmacokinetics and the enterohepatic recirculation of total ezetimibe.
Soulele K; Karalis V
Xenobiotica; 2019 Apr; 49(4):446-456. PubMed ID: 29629619
[TBL] [Abstract][Full Text] [Related]
12. Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.
Solms A; Reinecke I; Fiala-Buskies S; Keunecke A; Drenth HJ; Bruix J; Meinhardt G; Cleton A; Ploeger B
Eur J Pharm Sci; 2017 Nov; 109S():S149-S153. PubMed ID: 28549676
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
Schmulenson E; Bovet C; Theurillat R; Decosterd LA; Largiadèr CR; Prost JC; Csajka C; Bärtschi D; Guckenberger M; von Moos R; Bastian S; Joerger M; Jaehde U
Br J Clin Pharmacol; 2022 Dec; 88(12):5336-5347. PubMed ID: 35831229
[TBL] [Abstract][Full Text] [Related]
14. Metabolic profiling of the anti-tumor drug regorafenib in mice.
Wang YK; Xiao XR; Xu KP; Li F
J Pharm Biomed Anal; 2018 Sep; 159():524-535. PubMed ID: 30055476
[TBL] [Abstract][Full Text] [Related]
15. Topical administration of regorafenib eye drops: phase I dose-escalation study in healthy volunteers.
Zimmermann T; Höchel J; Becka M; Boettger MK; Rohde B; Schug B; Kunert KS; Donath F
Br J Clin Pharmacol; 2018 May; 84(5):865-875. PubMed ID: 29315699
[TBL] [Abstract][Full Text] [Related]
16. A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial).
Suzuki T; Sukawa Y; Imamura CK; Masuishi T; Satake H; Kumekawa Y; Funakoshi S; Kotaka M; Horie Y; Kawai S; Okuda H; Terazawa T; Kondoh C; Kato K; Yoshimura K; Ishikawa H; Hamamoto Y; Boku N; Takaishi H; Kanai T
Clin Colorectal Cancer; 2020 Mar; 19(1):13-21.e3. PubMed ID: 31732439
[TBL] [Abstract][Full Text] [Related]
17. Regorafenib in the treatment of colorectal cancer.
Majithia N; Grothey A
Expert Opin Pharmacother; 2016; 17(1):137-45. PubMed ID: 26559195
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
19. Influx and Efflux Transporters Contribute to the Increased Dermal Exposure to Active Metabolite of Regorafenib After Repeated Oral Administration in Mice.
Al-Shammari AH; Masuo Y; Fujita KI; Yoshikawa Y; Nakamichi N; Kubota Y; Sasaki Y; Kato Y
J Pharm Sci; 2019 Jun; 108(6):2173-2179. PubMed ID: 30685396
[TBL] [Abstract][Full Text] [Related]
20. Regorafenib in gastrointestinal stromal tumors.
Sirohi B; Philip DS; Shrikhande SV
Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]